IN MATRICO™ Drug Discovery
Increasing predictiveness and confidence in drug discovery
for cancer, fibrosis, and other devastating diseases.
News
XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read MoreXylyx Bio and Cell&Soft Announce Strategic Partnership to Develop Next-Generation Cell Culture Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates,today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.
Read MoreWebinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform
Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present […]
Read MoreWebinar: Redefining cancer research with IN SITE™ Metastasis Kit
Metastasis is the dissemination of cancer cells to distant organs: bone, liver, and lung being the most common sites of metastasis. The lack of in-vitro models that recapitulate the tissue-specific extracellular matrix (ECM) in metastatic sites presents a significant barrier for better understanding the mechanisms driving tumor colonization and consequently to developing drugs that effectively […]
Read MoreXYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read MoreXylyx Bio and Cell&Soft Announce Strategic Partnership to Develop Next-Generation Cell Culture Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates,today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.
Read MoreWebinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform
Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present […]
Read MoreWebinar: Redefining cancer research with IN SITE™ Metastasis Kit
Metastasis is the dissemination of cancer cells to distant organs: bone, liver, and lung being the most common sites of metastasis. The lack of in-vitro models that recapitulate the tissue-specific extracellular matrix (ECM) in metastatic sites presents a significant barrier for better understanding the mechanisms driving tumor colonization and consequently to developing drugs that effectively […]
Read MoreXylyx Bio releases advanced disease model system to improve cancer drug discovery
More faithful representation of disease biology is key to identify drivers of metastasis and targets for therapeutic intervention. Xylyx Bio’s IN SITE™ Metastasis Kit incorporates native tissue bone, liver, and lung extracellular matrices to provide key features of site-specific microenvironments, allowing scientists to more accurately model cancer metastasis in common secondary sites.
Read MoreXylyx Bio offers advanced lung models to accelerate COVID-19-related drug development
Humanized IN MATRICO™ Lung Fibrosis Assay provides insight into efficacy of drug candidates consistent with clinical results, increasing predictiveness and accelerating decision making in development of drugs for lung fibrosis.
Read MoreAllevi Partners with Xylyx Bio to Create Liver Specific Bioinks
Only a handful of researchers and companies around the world are tackling liver-specific bioinks, and one of them is now Allevi. The Philadelphia-based biotech company has now partnered with Xylyx Bio, a pioneer in physiomimetic biomaterials, to introduce new tissue-specific bioinks with Decellularized Extracellular Matrix (dECM). Starting with the liver, they will seek to recapitulate the native tissue microenvironment in 3D bioprinting.
Read MoreXylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening
Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery. Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
Read More
Previous
Next
